Review

Highway to hell or magic smoke? The dose-dependence of Δ^9 -THC in place conditioning paradigms

Rimas A. Kubilius,^{1,2} Paul M. Kaplick,^{1,3,4} and Carsten T. Wotjak¹

¹Neuronal Plasticity Research Group, Department of Stress Neurobiology and Neurogenetics, Max Planck Institute of Psychiatry, 80804 Munich, Germany; ²Faculty of Biology, Ludwig Maximilian University of Munich, 82152 Planegg-Martinsried, Germany; ³Structural and Functional Plasticity of the Nervous System Group, Swammerdam Institute for Life Sciences, University of Amsterdam, 1098 XH Amsterdam, The Netherlands; ⁴Institute for Interdisciplinary Studies, University of Amsterdam, 1098 XH Amsterdam, The Netherlands

The prerequisites for responsible cannabis use are at the heart of current inquiries into cannabis decriminalization by policy makers as well as academic and nonacademic stakeholders at a global scale. Δ^9 -tetrahydrocannabinol (Δ^9 -THC), the prime psychoactive compound of the *cannabis sativa*, as well as cannabimimetics that resemble the pharmacological properties and psychological effects of Δ^9 -THC, lend themselves handsomely to the preclinical scrutiny of reward-related behavior because they carry marked translational value. Although a functional dichotomy of the psychological effects of Δ^9 -THC (rewarding versus aversive) has been abundantly reported in place conditioning (PC) paradigms, and might be best attributed to a dose-dependence of Δ^9 -THC, most PC studies with Δ^9 -THC feature no significant effects at all. Therefore, after decades of rigorous research, it still remains undetermined whether Δ^9 -THC generally exerts rewarding or aversive effects in rodents. Here, we set out to extrapolate the commonly alleged dose-dependence of the rewarding and aversive effects of Δ^9 -THC from the existing literature, at the behavioral pharmacological level of analysis. Specifically, our meta-analysis investigated: (i) the alleged bidirectional effects and dose-dependence of Δ^9 -THC in the PC test; (ii) methodological inconsistencies between PC studies; and (iii) other pharmacological studies on cannabinoids (i.e., dopamine release, anxiety, stress, conditioned taste aversion, catalepsy) to substantiate the validity of PC findings. Our findings suggest that: (i) Δ^9 -THC dose-dependently generates rewarding (1 mg/kg) and aversive (5 mg/kg) effects in PC; (ii) an inconsistent use of priming injections hampers a clear establishment of the rewarding effects of Δ^9 -THC in PC tests and might explain the seemingly contradictory plethora of nonsignificant THC studies in the PC test; and (iii) other pharmacological studies on Δ^9 -THC substantiate the dose-dependent biphasic effects of Δ^9 -THC in PC. A standardized experimental design would advance evidence-based practice in future PC studies with Δ^9 -THC and facilitate the pointed establishment of rewarding and aversive effects of the substance.

[Supplemental material is available for this article.]

Pathological cannabis use has been recognized by current nosologies as the continued compulsive consumption of cannabis in spite of clinically relevant psychological (e.g., impaired goal-directed behavior, criminal activity) and social consequences (e.g., cessation of recreational activities with the family or peers, failures in significant life roles). Cannabis Use Disorder is incorporated into the dimensional category of Substance-Related and Addictive Disorders of the DSM-5 (2014), and Cannabis Related Disorders are an integral part of the Mental and Behavioral Disorders due to Psychoactive Substance Use category of the ICD-10 (2016).

The recently proposed causation-based Research Domain Criteria Project (RDoC, Insel et al. 2010) might accommodate transdiagnostic, neurobiological mechanisms underpinning the formation and maintenance of pathological cannabis use in the positive valence system. This domain spans the following constructs: approach motivation, initial responsiveness to reward attainment, sustained/longer-term responsiveness to reward attainment, reward learning, and habit. These constructs represent a temporal progression of reward processing and, in their abnormal form, might also underlie the development of reward dysfunction and ensuing obsessive substance use and addictive behaviors. This

temporal course pays close attention to the hedonic response an organism initially elicits to the reward stimulus' psychoactivity ("liking"), to the incentive value that motivates an increased likelihood of future engagement with the reward ("wanting"), and to related positive reinforcing properties of the reward and learning of reward-outcome contingencies that, in the long term, may contribute to the development of physical and psychological dependence, habitual, impulsive, and compulsive behavior, and withdrawal responses upon reward unavailability (Berridge et al. 2009; Baskin-Sommers and Foti 2015).

This review commences with a brief introduction into the endocannabinoid system (ECS) and its role in reward-related and addictive behaviors. We proceed by outlining the parameters of place conditioning (PC) paradigms. The primary objective of this review is to disentangle the dose-dependent effects of Δ^9 -THC in PC paradigms in terms of place preference (CPP), conditioned place aversion (CPA), and lack of effects.

© 2018 Kubilius et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first 12 months after the full-issue publication date (see <http://learnmem.cshlp.org/site/misc/terms.xhtml>). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Corresponding author: wotjak@psych.mpg.de

Article is online at <http://www.learnmem.org/cgi/doi/10.1101/lm.046870.117>.

The endocannabinoid system

The neuromodulatory ECS is the prime neurobiological system that is involved in the mediation of the rewarding and reinforcing effects of Δ^9 -THC (Mechoulam et al. 2014; Gould 2015). This system comprises the G-protein coupled cannabinoid receptors type 1 (CB1R), type 2 (CB2R), and GPR55, ionotropic TRPV1 receptor, their endogenous ligands (endocannabinoids), and the related synthesizing and degrading enzymes (Di Marzo et al. 2015; Morales and Reggio 2017; Zou and Kumar 2018). Δ^9 -THC shows a comparable affinity to both CB1Rs (K_i -values ranging from 5.05 to 80.3 nM) and CB2Rs (K_i -values ranging from 3.13 to 75.3 nM; Pertwee 2008), and may also bind to GPR55 (Brown 2007). Furthermore, Δ^9 -THC-associated aversive effects were recently linked not only to CB1R (Monory et al. 2007), but also to CB2Rs (Han et al. 2017).

Another category of cannabinoids that is of great translational interest, and which has received considerable attention in the last decade, is synthetic cannabinoids (Pintori et al. 2017). Cannabimimetics, a group of synthetic cannabinoids that echo the pharmacological properties and rewarding effects of Δ^9 -THC, are part of a recent wave of new psychoactive substances (NPS) that are frequently used for recreational purposes (Miliano et al. 2016). However, the consumption of cannabimimetics is associated with much higher health risks than natural cannabinoids (e.g., extended psychoactivity, more side effects; Fattore and Fratta 2011; Brents and Prather 2014). Some of the most prominent synthetic cannabinoids are R-(+)-WIN55212, (-)-CP55940, and HU-210 (HU), all three of which binding among others to CB1R. Studies on consequences of synthetic cannabinoids on PC are surprisingly scarce compared to Δ^9 -THC and will thus not be further considered by us.

Cannabinoids and reward

Recent articles that reviewed the putative mechanisms linking cannabinoids to addictive behaviors have emphasized the genetic (López-Moreno et al. 2012; Szutorisz and Hurd 2018), molecular (Solinas et al. 2008; Panlilio et al. 2013; D'Addario et al. 2014), and cellular (Sidhpura and Parsons 2011; Covey et al. 2015; Parsons and Hurd 2015; Busquets-Garcia et al. 2018) levels of analysis, and have specified the involvement of the ECS in drug, food, social, and sexual reward processing (Solinas et al. 2008; Fattore et al. 2010a; Tarragon and Moreno 2018), with drug intake being prioritized over natural rewards in drug addictions (Hyman et al. 2006; Edwards and Koob 2010). Taking a behavioral pharmacological slant on cannabinoids and addictive behavior, further reviews have synthesized cross-species evidence for the existence of rewarding (“liking”) and reinforcing (“wanting”) effects of cannabinoids and their pharmacological efficiency (Tanda and Goldberg 2003; Murray et al. 2007; Haney 2008; Panlilio et al. 2010). As for the reinforcing properties of cannabinoids, reviews have delineated the unidirectional and reciprocal modulatory relationship of cannabinoids with substances of abuse (Maldonado et al. 2006; Serrano and Parsons 2011; Johnson and Lovinger 2016; Sloan et al. 2017) such as nicotine (Gamaledin et al. 2015; Scherma et al. 2016), opioids (Cooper and Haney 2009), ethanol/alcohol (López-Moreno et al. 2010; Pava and Woodward 2012; Kleczkowska et al. 2015), and psychostimulants like cocaine (Hayase 2017) and amphetamines (Wiskerke et al. 2008; Su and Zhao 2017). While analyses of cannabinoid modulation of the reinforcing effects of substances of abuse have unearthed a crucial role of the ECS (Tzschentke 2007; Wills and Parker 2016), the defining action of cannabinoid agonists is of utmost interest to current inquiries into responsible cannabis consumption by policy makers and academic and nonacademic stakeholders. Moreover, most of the listed articles contain summarized data ascertained in self-

administration paradigms that rest on distinct operant learning mechanisms and advance our knowledge of the reinforcing effects (i.e., “wanting”) of cannabinoids. Yet, other behavioral assays are at hand to exclusively tackle the rewarding effects of CB1R agonists, and Δ^9 -THC specifically, based on Pavlovian learning. These assays are valuable tools that aid the development of a mechanistic explanation of the initial responsiveness to Δ^9 -THC reward attainment (i.e., “liking”). The most prominent of such paradigms is the Place Conditioning test (PC; Mackintosh 1974; Bardo and Bevins 2000; Bevins and Cunningham 2006). The PC has ubiquitously yielded a CB1R- and dose-dependence of rewarding biphasic (relaxation versus anxiety/paranoia) conditioned effects (Cooper and Haney 2008, 2009; Sanchis-Segura and Spanagel 2006; Tzschentke 2007; Murray and Bevins 2010), thereby hinting at the particular suitability of this test for cannabinoid pharmacological behavioral research.

Conditioned place preference and avoidance

The PC paradigm is the most popular form of conditioned preference procedures and can operationalize rewarding and aversive effects of a substance. In this test, an animal—typically a rodent—is exposed to a behavioral apparatus in which it encounters two or three compartments, separated by removable doors (Tzschentke 2007). Variations in apparatus design complicate conclusive result interpretation, and partially explain differences in outcome studies in PC paradigms (Murray and Bevins 2010). We will succinctly introduce some of the fundamental PC experimental variables to familiarize the “uninformed” reader (cf. Fig. 1).

Compartments

In a two-compartment setting, each of the equally sized chambers accommodates distinctive environmental cues—of visual, tactile, and/or olfactory nature—to provide the animal with a unique perception of each area. In drug-induced PC, a substance/drug (unconditioned stimulus) is associated with one compartment (i.e., the drug-paired compartment, DPC, conditioned stimulus) and a vehicle is paired with the other compartment (vehicle-paired compartment, VPC). In three-compartment settings, the chambers at either end are slightly larger than the concentric box (nonpaired compartment), which remains as a neutral place of retreat, and only the two side compartments are used for drug- and vehicle-pairings.

Procedural designs

In an unbiased design the administered drug is associated with a compartment that is arbitrarily chosen by the experimenter, irrespective of any innate preference of the animal for one of the two compartments. In a biased design, an initial preference for either of the two conditioning compartments represents a crucial variable (Sanchis-Segura and Spanagel 2006), and the drug is either paired with the preferred or nonpreferred compartment. Several studies have concluded that unbiased procedures and balanced apparatus construction is crucial, specifically for cannabinoid-related PC research (Cunningham et al. 2003; Roma and Riley 2005; Murray and Bevins 2010).

Phases

The entire PC procedure is divided into three distinct phases: pre-exposure, conditioning, and testing. During pre-exposure, the animal is placed in the nonpaired compartment (NPC) of the three-compartment apparatus or at the transition between the DPC and VPC in the two-compartment apparatus, and can gain free access to all compartments. Consequently, rodents get

Figure 1. Schematic illustration of the PC paradigm. (A) 2-compartment apparatus. (B) 3-compartment apparatus. Conditioned place preference (CPP) is established by either significantly more time spent in the drug-paired compartment (DPC) after conditioning than before (i.e., test versus preexp. DPC) or significantly more time spent in the DPC than in the vehicle-paired compartment (VPC) during test (i.e., DPC versus VPC). Conditioned place aversion (CPA) is operationalized by either significantly less time spent in the DPC after conditioning than before (i.e., test versus preexp. DPC) or significantly less time spent in the DPC than in the VPC during test (i.e., DPC versus VPC). In a three-compartment setting, the time spent in the nonpaired compartment (NPC) is in most studies not included into the measurement of a CPP or CPA.

accustomed to the environmental cues associated with the compartments (no drugs being administered), the time spent in the DPC and VPC is measured, and an initial preference for the compartments is tested. In the conditioning phase, rodents are administered the drug or vehicle before being introduced into the drug-paired or the VPC for 30 min. These pairings of drug and vehicle with the different compartments are repeated in an alternating fashion over several days (trials) to augment the conditioning process. Some studies administer an additional drug injection 1 or 2 d before starting with the conditioning procedure to provide a preexperience of the drug effects (drug priming), which is supposed to ameliorate possible aversive responses to the drug. In the test phase, the development of an approach or avoidance of the DPC is tested in a drug-free state. Analogous to the preexposure, the rodents are placed in the center of the apparatus.

Quantification methods

A CPP of the administered substance is established when the animal spends either significantly more time in the DPC after conditioning than before (i.e., test versus preexp. DPC) or spends significantly more time in the DPC than in the VPC during test (i.e., DPC versus VPC). A conditioned place aversion (CPA) is established when the animal spends either significantly less time in the DPC after conditioning than before (i.e. test versus preexp. DPC) or spends significantly less time in the DPC than in the VPC during test (i.e., DPC versus VPC) (Tzschentke 2007). In a three-compartment setting, the time spent in the NPC is in most studies not included into the measurement of CPP or CPA.

Dose-dependence of the rewarding effects of Δ^9 -THC

Behavioral pharmacological studies in rodents traditionally ascertain the efficiency of cannabinoids through assessment of the tet-

rad, which comprises (i) decreased locomotion (e.g., open-field test, hole-board), (ii) decreased body temperature, (iii) increased analgesia (e.g., hot plate or tail immersion test), and (iv) increased catalepsy (e.g., bar test). Other than for the tetrad (Monory et al. 2007), tests of fear and anxiety have revealed a biphasic nature of Δ^9 -THC pharmacological action. Low doses of CB1R agonists (≤ 1 mg/kg) tend to induce anxiolytic and hence potentially rewarding effects (Moreira and Wotjak 2010), whereas high doses (>1 mg–10 mg/kg) and pharmacological blockage of CB1R (Marsicano et al. 2002) engender anxiogenic (Viveros et al. 2005; Patel and Hillard 2006; Micale et al. 2013) and psychotogenic (Bhattacharyya et al. 2009, 2010) effects.

PC studies on highly addictive drugs, such as psychostimulants and opiates (e.g., heroin), clearly reveal the rewarding properties of these drugs (marked establishment of CPPs). It also seems to be well-established that natural and synthetic cannabinoids produce CB1R-dependent CPA in high doses and CPP in lower doses (Murray et al. 2007; Murray and Bevins 2010; Wills and Parker 2016; Pintori et al. 2017). However, even though the bidirectional effects of Δ^9 -THC on PC might be ascribed to a

dose-dependence, what still remains apparently inconclusive is that most studies with Δ^9 -THC feature no significant effects on PC at all.

Lead questions

The principal question of this study revolves around the generality of the rewarding or aversive effects of Δ^9 -THC in rodent PC studies and the reasons for the frequently observed inefficacy of treatment. Specifically, our meta-analysis: (i) weighs the evidence for the hypothesized bidirectional effects (rewarding versus aversive) and dose-dependence of Δ^9 -THC, in the PC paradigm, (ii) contains an examination of methodological inconsistencies between studies, and (iii) relates the findings from PC experiments to other pharmacological studies on cannabinoid pharmacology (i.e., dopamine release, anxiety, stress, conditioned taste aversion, catalepsy).

Materials and Methods

Inclusion/exclusion criteria for the systematic review

The selection of studies in the present analysis is aimed at shifting the focus of current review activities to the most relevant translational research on cannabinoids and reward-related behavior. Therefore, we have targeted PC studies (two- or three-compartment PC apparatus) that solely used exogenous cannabinoid administration (without any pre-, co-, or post-treatment with any other substances) via intraperitoneal (i.p.) and intravenous (i.v.) injections in rodents (mice and rats), with food and water ad libitum. Food intake and energy balance are known to modulate the metabolism of endocannabinoids (Matias and Di Marzo 2006; Cristino et al. 2014), which is why research with deprivational protocols has been excluded. Studies on other substances have also evinced that food restriction appears to exert crucial, long-lasting influences on PC procedures which even persist in mice re-fed ad

libitum (Cabib et al. 2000). Furthermore, a pulmonary route of administration makes use of an intriguing approach, given that humans prevalently consume cannabis through inhalation (i.e., by smoking). However, compared to i.p. or i.v. injections, the pulmonary uptake of vaporized substances produces qualitatively different effects on behavior, most presumably due to pharmacokinetic differences (Manwell et al. 2014). Moreover, due to the lack of evidence about plasma concentration that results from pulmonary administration protocols, a comparison of dose-response-relationships with i.p. and s.c. treatment is practically impossible. Therefore, such studies were also discounted in the present article. Furthermore, as PC studies with Δ^9 -THC almost exclusively resort to male rodents and only few assessed age-dependencies, we did not factor in sex and age as methodological traits. The systemic literature search was conducted using several databases, including Web of Science, Scopus, and Pubmed. Search terms encompassed: Δ^9 -THC, THC, cannabinoid receptor type 1, CB1R, cannabinoids, cannabis, reward, addiction, behavior, dose, dosage, CPP, CPA, and PC.

All selected PC studies are listed in the **Supplemental Material** (Supplemental Table 1), juxtaposing different methodological traits concerning test animals (species, strain) and procedural aspects of PC (drug compound, dose, priming, PC design [biased, unbiased], number of compartments, PC quantification method). The total amount of PC experiments conducted with Δ^9 -THC and considered in this article encompasses 73 assessments. When referring to individual PC experiments and their results, it must be noted that each group of animals, which was exposed to a different treatment or procedure, was counted separately—including the groups belonging to the same study.

Methodology of the meta-analysis

Here, dose-dependent differences of Δ^9 -THC were first tested between the selected PC assessments, establishing either a CPP, CPA, or no significant effects (NEs). Second, upon discovering that significant differences in dose dependence could only be established by comparing CPAs with CPPs and CPAs with NEs, it remained questionable why there are no significant differences between CPPs and NEs. To further examine the high cooccurrence of CPPs and NEs at similar dose-ranges, procedural parameters other than the dose of Δ^9 -THC were tested for differences. To this end, five methodological parameters were more closely scrutinized: (rat-)strain, drug priming, PC design (biased versus unbiased), PC quantification method, and number of compartments. Kruskal-Wallis test followed by Dunn's multiple comparison tests were applied for dose-dependence comparisons (CPPs versus CPAs versus NEs) and the χ^2 test for procedural differences (CPPs versus NEs). Third, to further substantiate that Δ^9 -THC exerts positive internal states at low doses and negative internal states at high doses, the dose-dependence of CPPs and CPAs were compared with animal studies assessing other Δ^9 -THC behavioral and physiological traits. To this end, studies on Δ^9 -THC-induced stress (corticosterone secretion), catalepsy, conditioned taste aversion, and anxiety (anxiogenic-like effects) were selected to substantiate causality between CPA findings and high doses of Δ^9 -THC. Conversely, studies on the anxiolytic-like effects of Δ^9 -THC, on Δ^9 -THC-induced dopamine release in the mesocorticolimbic system, and on Δ^9 -THC self-administration (SA) were consulted to conceivably corroborate a causal link between CPP and low doses of Δ^9 -THC. Wilcoxon signed rank test (one-sided question) were used for dose-dependent comparisons (PC versus other Δ^9 -THC pharmacological effects). Statistical significance was accepted if $P < 0.05$.

Results

Dose-range

The dose range of Δ^9 -THC in all considered PC experiments extends from a minimal concentration of 0.01 mg/kg to a maximal concentration of 20 mg/kg. Altogether 45 PC assessments with Δ^9 -THC administration were conducted with rats (62%) and

28 with mice (38%). The highest amount of PC experiments for both mice and rats results in the dose range of $0 \text{ mg/kg} < \text{dose} \leq 1 \text{ mg/kg}$ (>50%), followed by the dose range of $1 \text{ mg/kg} < \text{dose} \leq 5 \text{ mg/kg}$ (>35%), and only very few studies at concentrations higher than 5 mg/kg (Fig. 2A).

Efficacy of treatment

By far the majority of studies (>50%) failed to reveal any effect of Δ^9 -THC at all (NE; Fig. 2A), and only a minority reported the occurrence of CPP or CPA (~25%, each; Fig. 2A).

Parametric analysis of CPP

In mice, all experiments were conducted by using an unbiased CPP design with an apparatus consisting of three compartments, except for one study with an unstated design. In rats, CPP was established with an unbiased design as well (except one study not stating the design). Only the number of compartments differs with five experiments using a two-compartment and three experiments using a three-compartment apparatus. To estimate CPP, the time spent in the DPC during preexposure and the test-phase (test versus preexp. DPC) was compared in all mouse assays (100%) and in six with rats (67%). The prevalently used strains in mice were CD-1 (67%), and in rats Long-Evans (33%) and Wistar (44%).

Figure 2. Prevalence and dose-dependency of CPP, CPA, and nonsignificant effects (NE) with Δ^9 -THC. (A) The majority of studies has been performed with doses $\leq 1 \text{ mg/kg}$, and failed to reveal any effect at all (NE). (B) Dose-dependent distribution of CPPs, aversions (CPA), and no significant effects (NE) with Δ^9 -THC [KW(3) = 24.12, (***) $P < 0.0001$, Kruskal-Wallis, followed by Dunn's multiple post hoc test]. (C) Studies with drug priming show a bias toward the development of CPP, whereas studies without drug priming often fail to reveal any effect [$\chi^2(1) = 6.352$, (\$) $P = 0.0117$].

Parametric analysis of CPA

Virtually no priming injections were administered in both mice and rats. Δ^9 -THC conditioning with mice was undertaken by predominantly using an unbiased design. Likewise, an unbiased design was mostly used with rats (82%). A three-compartment apparatus was prevalently used with mice (88%). In contrast, four assessments with three compartments (36%) and seven with two compartments (64%) were performed in rats. In mice, CPA was predominantly determined by comparing the time spent in the compartment during preexposure and test phase (test versus preexp. DPC; 88%). On the contrary, both test versus preexp. DPC and DPC versus VPC test comparisons were performed in rats. The used rat strains were Wistar, Long-Evans, Sprague-Dawley, and Lister Hooded. In mice, C57BL/6J, F4, and F5 generation backcrosses to C57BL/6 and 1:1 hybrids of 129/SV and C57BL/6J were used in addition to CD-1 mice.

Parametric analysis of experiments with no significant effects (NEs)

Except for a few biased assessments with rats (28%), most studies in mice and rats used the unbiased design. Again the three-compartment setup predominated studies in mice, but was applied only in half of the rat studies. Data were analyzed by comparing the time spent in the DPC during preexposure and test phase in the majority of studies. The strains used in these unsuccessful experiments in rats were mainly Sprague-Dawley (40%) and Wistar (44%), and CD-1 in mice (64%).

Δ^9 -THC dose-dependence of CPPs, CPAs, and NEs

A dose-dependent distribution of PC experiments is illustrated separately for CPPs, NEs, and CPAs in Figure 2B. CPPs were established with doses ranging from 0.075 to 4 mg/kg (mice: 1 mg/kg; rats: 0.075–4 mg/kg). CPAs, on the other hand, were implemented at doses reaching from 1 to 20 mg/kg (mice: 5–20 mg/kg; rats: 1–15 mg/kg). Unsuccessful experiments range from 0.01 to 10 mg/kg (mice: 0.3–10 mg/kg; rats: 0.01–10 mg/kg). The median values for CPAs are 5 mg/kg compared to 1 mg/kg for CPPs and NEs. We tested for systematic dose effects in CPPs, NEs, and CPAs, and obtained significant group differences (KW(3)=24.12, $P < 0.0001$), indicating that animals treated with higher doses of Δ^9 -THC more often developed CPA than CPP or NE (Fig. 2B).

Comparison of methodological implementations between CPPs and NEs

As a dose-related comparison did not reveal significant group differences between CPPs and NEs, we compared other procedural measures such as rat strains, drug priming, PC designs, PC quantifications, and the number of compartments between experiments resulting either in CPP or NE. No other procedural traits were significantly different between CPPs and NEs, except for priming injections (priming: $\chi^2(1) = 6.352$, $P = 0.0117$; cf. Fig. 2C).

Dose-dependence of appetitive versus aversive effects of Δ^9 -THC in other animal studies

To investigate the putative causal link between the dose ranges of Δ^9 -THC and the establishment of a CPP or CPA, PC findings with Δ^9 -THC were dose-dependently compared with other pharmacological effects of Δ^9 -THC (i.e., increase in dopamine release, anxiolytic/anxiogenic-like effects, corticosterone secretion, conditioned taste aversion, and catalepsy). The studies on these pharmacological effects are listed, along with their findings, in [Supplemental Table 2](#). The dose-dependent comparison of the aforementioned results with PC findings on Δ^9 -THC is illustrated

in Figure 3. Dopamine release and anxiolytic-like effects induced by Δ^9 -THC seemed appropriate to be taken as indicators for “pleasant” effects, given that the release of dopamine in the mesolimbic system is generally acknowledged to play a crucial role in reward and reinforcement, while the anxiolytic-like effects provide an alleviation of fear and anxiety. On the other hand, we referred to traits such as Δ^9 -THC-induced anxiogenic-like effects, corticosterone secretion, conditioned taste aversion, and catalepsy as indicators for “unpleasant” effects.

The dose-ranges of dopamine release (0.15 mg/kg $\leq$ dose $\leq$ 5 mg/kg) and anxiolytic-like effects (0.075 mg/kg $\leq$ dose $\leq$ 1.5 mg/kg) tendentially corresponded to the dose range of CPPs (0.075 mg/kg $\leq$ dose $\leq$ 4 mg/kg). In contrast, the dose ranges of anxiogenic-like effects (0.5 mg/kg $\leq$ dose $\leq$ 10 mg/kg), corticosterone secretion (2 mg/kg $\leq$ dose $\leq$ 20 mg/kg), conditioned taste aversion (0.56 mg/kg $\leq$ dose $\leq$ 32 mg/kg) and catalepsy (10 mg/kg $\leq$ dose $\leq$ 50 mg/kg) overlapped rather with the dose-range of CPAs (1 mg/kg $\leq$ dose $\leq$ 20 mg/kg) than with CPPs (0.075 mg/kg $\leq$ dose $\leq$ 4 mg/kg; Fig. 3). However, both the dose ranges of dopamine release and anxiolytic-like effects on one hand and the dose ranges of anxiogenic-like effects, corticosterone secretion, and conditioned taste aversion on the other overlapped with the dose-range of NEs (Fig. 3).

In relation to the median of CPPs (1 mg/kg) and NEs (1 mg/kg), the medians of anxiogenic-like effects (2.5 mg/kg), corticosterone secretion (5 mg/kg), conditioned taste aversion (2.5 mg/kg), and catalepsy (17.5 mg/kg) lay above it. As opposed to this, the median of anxiolytic-like effects (0.34 mg/kg) lay below it and that of dopamine release (1 mg/kg) equaled it. Taking instead the median of CPAs as a reference point (5 mg/kg), it is notable that the median of corticosterone secretion equaled it. Furthermore, the only median that lay above the median of CPAs is that of catalepsy (Fig. 3). To test for significant difference between the dose-dependency of CPPs and CPAs and the dose-dependency of the other pharmacological effects of Δ^9 -THC, a Wilcoxon signed rank test (one-sided question) was applied. While on one hand the test revealed that the doses of Δ^9 -THC for dopamine release and anxiolytic-like effects were significantly different from the median dose of Δ^9 -THC to establish CPAs (5 mg/kg), it evinced on the other hand that the doses of Δ^9 -THC for corticosterone secretion, conditioned taste aversion, and catalepsy (but not for anxiogenic-like effects) were significantly different from the median dose of Δ^9 -THC to establish CPPs (1 mg/kg) (Fig. 3).

Figure 3. Other dose-dependent appetitive (green) and aversive (red) effects of Δ^9 -THC. Results of individual experiments/groups are plotted as black dots (median values as black lines); statistics: Wilcoxon signed rank test (one-sided question), $P < 0.05$ versus median of CPA and CPP, respectively. Median values of CPPs (1 mg/kg), CPAs (5 mg/kg), and NEs (1 mg/kg; cf. Fig. 2B) are incorporated as green, red, and gray dashed lines, respectively; dose ranges of CPPs, CPAs, and NEs are illustrated in the respective (yet fainter) colors. # (red) $p < 0.05$ versus median of CPA, # (green) $p < 0.05$ versus median of CPP (Wilcoxon signed test).

Discussion

Despite the considerable progress made in the neurosciences to study the mechanistic underpinnings of the pharmacology of cannabinoids, studies on Δ^9 -THC continue to provide seemingly inconclusive findings, which hamper an explanation of cannabis reward, not to mention cannabis addiction. Here, we sought to investigate the effects of Δ^9 -THC on the PC procedure to sharpen our knowledge of the contended involvement of exogenous cannabinoids in reward-related processes (specifically the “liking” domain) that are allegedly affiliated to drug addiction. Data substantiated (i) the dose-dependence of the bidirectional effects of Δ^9 -THC on PC (CPPs at low doses [1 mg/kg] versus CPAs at high doses [5 mg/kg]), (ii) identified significant methodological inconsistencies between CPPs and NEs with Δ^9 -THC, specifically regarding the application of priming injections, and (iii) elucidated the conformity of PC findings with other pharmacological effects of Δ^9 -THC (dopamine release, anxiety, stress as indexed by increased corticosterone secretion, conditioned taste aversion, and catalepsy), thus exhaustively corroborating the validity of CPPs and CPAs as a dose-dependent measure for the rewarding and aversive effects of Δ^9 -THC.

Dose-dependence

Considering that cannabis is expected to have highly rewarding properties, it is surprising that slightly more studies reported the occurrence of CPA rather than CPP. The dose-dependent juxtaposition of CPPs, CPAs, and NEs clearly demonstrated that the dose ranges of NEs markedly overlap with the dose ranges of CPPs and, in part, also CPAs. When testing for significant group differences, it was possible to reveal that animals treated with higher doses of Δ^9 -THC more often developed a CPA than a CPP or NE. This finding is in accordance with common conjectures, stating that high doses of Δ^9 -THC elicit aversive effects (Murray et al. 2007; Murray and Bevins 2010). In line with the evidence that Δ^9 -THC exerts bidirectional effects in a dose-dependent manner (Valjent et al. 2002; Murray et al. 2007; Murray and Bevins 2010; Rey et al. 2012), post-hoc group comparisons yielded significant differences in dose range between CPPs (occurring rather at low doses Δ^9 -THC) and CPAs (occurring rather at high doses Δ^9 -THC). However, when comparing these two groups with the dose range of NEs, only CPAs could be set apart, while no significant difference in dose-dependence between CPPs and NEs was found. This is unexpected considering that the PC paradigm has entrenched itself as an adequate procedure to assess both rewarding and aversive effects of drugs (Sanchis-Segura and Spanagel 2006; Tzschentke 2007; Murray and Bevins 2010). Furthermore, given that cannabis is such a highly desired recreational drug and that even self-administration studies have unambiguously shown that squirrel monkeys readily self-administer Δ^9 -THC (Tanda et al. 2000; Justinova et al. 2003, 2004), it seems hardly comprehensible why the rewarding effects of Δ^9 -THC are rather tricky to unveil in PC studies with rodents. However, the high incidence of NEs and the overlapping dose range with CPP is conform with the assumption that Δ^9 -THC has only weak reinforcing properties, at least in rodents, compared to other psychotropic drugs (Justinova et al. 2005). The situation might be different, if an experiment would be performed with stressed animals in an anxiety-like state, where low doses of Δ^9 -THC may ameliorate the negative affect (Riebe et al. 2012; Micale et al. 2013; Bedse et al. 2017; Patel et al. 2017) and, if combined with a distinct test compartment, might favor the development of CPP. The possibility that Δ^9 -THC interferes with cognitive processes, and thus hinders the establishment of CPP is rather unlikely, given the occurrence of memory-dependent CPA at higher doses.

Procedural differences between CPPs and NEs with Δ^9 -THC

We also assessed whether the failure to induce CPP at lower doses (0 mg/kg < dose $\leq$ 1 mg/kg) relates to procedural differences in studies reporting CPP versus NE. Among the many parameters considered, only drug priming injections seem to favor CPPs versus NEs. Pretreatment with a drug prior to PC (priming) is an acknowledged way to habituate animals to the injection procedure and effects of the drug. This is expected to diminish possible aversive effects, which might occur in drug-naïve animals (Valjent and Maldonado 2000; Quinn et al. 2008). Some PC studies also clearly showed that priming injections can play a critical role in avoiding NEs. For instance, in a 1 mg/kg Δ^9 -THC PC study (Valjent and Maldonado 2000), two separate PC assessments were implemented: Animals not pretreated with the drug before the assessment (no priming) showed no significant effects on PC, whereas priming resulted in a CPP, suggesting that there appeared to be a higher susceptibility in animals with a drug preexperience to develop a significant behavioral response (CPP) to low doses of Δ^9 -THC, than in naïve animals. The exact molecular underpinnings of drug priming are not clear. They may include intracellular signaling processes (Cannich et al. 2004) and receptor desensitization/internalization (e.g., Dudok et al. 2015).

PC versus other pharmacological effects of Δ^9 -THC

Leaving all nonsignificant PC findings aside, CPPs was clearly ascribed to low doses of Δ^9 -THC (median: 1 mg/kg) and CPAs to high doses of Δ^9 -THC (median: 5 mg/kg). When other behavioral and neurochemical readouts are considered, there is a remarkable overlap in the dose-response relationship with appetitive (e.g., dopamine release in the mesolimbic system, anxiolytic effects), respectively aversive consequences of Δ^9 -THC treatment (e.g., anxiogenic effects, increased corticosterone secretion, conditioned taste aversion). The reduction in locomotor activity and the incidence of catalepsy (Monory et al. 2007; Viñals et al. 2015) at high Δ^9 -THC concentrations may not only cause discomfort to the animals, but also interfere with information gathering and, thus, learning processes.

If the biphasic consequences of CB1R agonists on anxiety-like behavior (Rey et al. 2012) can be generalized to other behavioral tasks, low doses of Δ^9 -THC may promote CPP via CB1R on cortical glutamatergic neurons, whereas high doses induce CPA via CB1R on GABAergic neurons. Hence, CB1R on different neuronal populations hold the balance between appetitive and aversive behavior. It is conceivable that drug priming may shift this balance toward appetitive behavior, likely by differentially affecting CB1R signaling on GABAergic versus glutamatergic neurons. Future studies should use cell-type specific CB1R knockout mice to validate those assumptions.

Procedural design to pointedly establish a CPP or a CPA

Overall, we can say that the PC paradigm is a valid method to assess the dose-dependent biphasic nature of Δ^9 -THC, even though it remains rather tricky to unveil the rewarding effects of Δ^9 -THC. This intricacy may, in part, be ascribed to the rather weak rewarding and reinforcing effects of Δ^9 -THC. However, the comparability of PC findings and thus their evaluation are also significantly hampered by the differences in PC methodology. Thus, it is crucial that future PC studies prevalently resort to standardized and entrenched procedures.

In light of our findings, we suggest a procedural design to pointedly establish both a CPP as well as CPA. We limit our suggestions to the methodological traits evaluated in the meta-analysis alongside with a few other traits, which have proven to be suitable parameters in past studies (Box 1).

Box 1. Prototypic experimental PC design to pointedly study CPP vs. CPA with Δ^9 -THC in mice

Experimental subjects

Adult male C57BL/6 mice ($n \geq 8$).

Place conditioning

On basis of the unbiased design with a three-compartment apparatus over the course of eight consecutive days (treatment with Δ^9 -THC on uneven and with vehicle on even days; length of conditioning session: 30 min, with the animals confined either to the drug-paired or the vehicle-paired compartment), preceded by a pre-exposure session (15 min; 24 h before starting with PC) and followed by the test session (15 min; 24 h after finishing with PC) with free exploration of three compartments. CPP or CPA is assessed by comparing the time spent in the drug-paired compartment during the test session vs. preexposure.

Treatment

Mice will be treated either with 1 mg/kg Δ^9 -THC (CPP) or 5 mg/kg Δ^9 -THC (CPA) i.p. before placement into the drug-paired compartment. In CPP, mice are primed with 1 mg/kg Δ^9 -THC before starting with the PC in order to accustom them to potential side effects of the treatment.

Sex and age

Specific knowledge about the sex-dependence of the rewarding effects of Δ^9 -THC is sketchy, given that PC studies with Δ^9 -THC have been conducted almost exclusively with male rodents (Hempel et al. 2017). This rather ungrounded negligence of sex differentiation is an issue that needs to be addressed in future PC studies. In fact, sex-differences in cannabis use have become a rather current topic: A growing number of women has been reported to use cannabis more frequently and with a higher propensity to develop cannabis use disorder than men (Cooper and Craft 2018). This might be interrelated with findings showing that women use cannabis at a faster rate, that they exhibit a higher sensitivity to its reinforcing effects, and that they develop more severe withdrawal symptoms than men (Marusich et al. 2014; Cooper and Craft 2018).

Preclinical studies have yielded sex-dependent differences in CB1R density and G-protein activation (Rubino and Parolaro 2011; Cooper and Craft 2018). Furthermore, it has been specified that female animals self-administer synthetic cannabinoids faster and at higher rates than males and are more susceptible to drug and cue-induced reinstatement (Fattore et al. 2007, 2010b; Hempel et al. 2017). The implications of these findings are not yet entirely clear. Albeit, sex might be an important factor involved in the increased sensitivity to the rewarding as well as reinforcing properties of cannabinoids (Fattore et al. 2007, 2010b; Hempel et al. 2017) and the development of stronger withdrawal symptoms in females (Harte-Hargrove and Dow-Edwards 2012). However, more studies investigating the putative sexual dimorphism of cannabinoid reward and reinforcement are needed on both physiological and behavioral levels, in order to uncover the underlying mechanisms.

The need of further investigations applies likewise to the age-dependence of the rewarding effects of Δ^9 -THC. Even though few in number, the existing studies clearly show a trend of adult rodents perceiving the effects Δ^9 -THC as more aversive than adolescents (Schramm-Sapota et al. 2007; Quinn et al. 2008; Pandolfo et al. 2009). Cannabis use and the development of cannabis use disorder are more frequent in adolescent users relative to middle-aged and older adults (Haug et al. 2017). Thus, it

would be reasonable to assess the relation between the afore-described trend, observed in preclinical studies, with human behavior more in depth. For this, more physiological and behavioral studies on the relation between age and cannabis reward are required.

Conclusions

Δ^9 -THC holds the potential to induce both CPP and CPA, depending on the dose. The high incidence of negative findings, however, speaks against strong reinforcing properties of Δ^9 -THC and might result from competing appetitive versus aversive consequences of the treatment, which outbalance each other. Drug priming seems to shift the balance toward appetitive consequences, since it favors the occurrence of CPP. Future studies should consider animals of both sexes at different developmental stages (e.g., adolescence versus adulthood) and internal states (e.g., stressed versus non-stressed, food-restricted versus ad libitum fed) to more closely resemble the situations in humans. At the same time, more effort has to be done to disentangle the rewarding properties of Δ^9 -THC in terms of “liking” versus “wanting” (e.g., by using self-administration paradigms).

References

- Bardo MT, Bevins RA. 2000. Conditioned place preference: what does it add to our preclinical understanding of drug reward? *Psychopharmacology* **153**: 31–43.
- Baskin-Sommers AR, Foti D. 2015. Abnormal reward functioning across substance use disorders and major depressive disorder: considering reward as a transdiagnostic mechanism. *Int J Psychophysiol* **98**: 227–239.
- Bedse G, Hartley ND, Neale E, Gaulden AD, Patrick TA, Kingsley PJ, Uddin MJ, Plath N, Marnett LJ, Patel S. 2017. Functional redundancy between canonical endocannabinoid signaling systems in the modulation of anxiety. *Biol Psych* **82**: 488–499.
- Berridge KC, Robinson TE, Aldridge JW. 2009. Dissecting components of reward: ‘liking’, ‘wanting’, and learning. *Curr Opin Pharmacol* **9**: 65–73.
- Bevins RA, Cunningham CL. 2006. Place conditioning: a methodological analysis. In *Tasks and techniques: a sampling of the methodologies for the investigation of animal learning, behavior and cognition* (ed. Anderson MJ), pp. 99–110. Nova Science Publishers, Inc., New York.
- Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O’Carroll C, Allen P, Seal ML, Fletcher PC, Crippa JA. 2009. Modulation of mediotemporal and ventrostriatal function in humans by Δ^9 -tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. *Arch Gen Psych* **66**: 442–451.
- Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O’Carroll CM, Seal M, Allen P, et al. 2010. Opposite effects of Δ^9 -tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. *Neuropsychopharmacology* **35**: 764–774.
- Brents LK, Prather PL. 2014. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. *Drug Metab Rev* **46**: 72–85.
- Brown AJ. 2007. Novel cannabinoid receptors. *Br J Pharmacol* **152**: S67–S75.
- Busquets-García A, Bains J, Marsicano G. 2018. CB1 receptor signaling in the brain: extracting specificity from ubiquity. *Neuropsychopharmacology* **43**: 4–20.
- Cabib S, Orsini C, Le Moal M, Piazza PV. 2000. Abolition and reversal of strain differences in behavioral responses to drugs of abuse after a brief experience. *Science* **289**: 463–465.
- Cannich A, Wotjak CT, Kamprath K, Hermann H, Lutz B, Marsicano G. 2004. CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice. *Learn Mem* **11**: 625–632.
- Cooper ZD, Craft RM. 2018. Sex-dependent effects of cannabis and cannabinoids: a translational perspective. *Neuropsychopharmacol* **43**: 34–51.
- Cooper ZD, Haney M. 2008. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. *Addict Biol* **13**: 188–195.
- Cooper ZD, Haney M. 2009. Actions of Δ^9 -tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. *Int Rev Psych* **21**: 104–112.
- Covey DP, Wenzel JM, Cheer JF. 2015. Cannabinoid modulation of drug reward and the implications of marijuana legalization. *Brain Res* **1628**: 233–243.

- Cristino L, Becker T, Di Marzo V. 2014. Endocannabinoids and energy homeostasis: an update. *Biofactors* **40**: 389–397.
- Cunningham CL, Ferree NK, Howard MA. 2003. Apparatus bias and place conditioning with ethanol in mice. *Psychopharmacology* **170**: 409–422.
- D'Addario C, Micioni Di Bonaventura M, Pucci M, Romano A, Gaetani S, Ciccocioppo R, Maccarrone M. 2014. Endocannabinoid signaling and food addiction. *Neurosci Biobehav Rev* **47**: 203–224.
- Di Marzo V, Stella N, Zimmer A. 2015. Endocannabinoid signalling and the deteriorating brain. *Nat Rev Neurosci* **16**: 30–42.
- Dudok B, Barna L, Ledri M, Szabó SI, Szabadits E, Pintér B, Woodhams SG, Henstridge CM, Balla GY, Nyilas R, et al. 2015. Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling. *Nat Neurosci* **18**: 75–86.
- Edwards S, Koob GF. 2010. Neurobiology of dysregulated motivational systems in drug addiction. *Future Neurol* **5**: 393–410.
- Fattore L, Fratta W. 2011. Beyond THC: the new generation of cannabinoid designer drugs. *Front Behav Neurosci* **5**: 60.
- Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W. 2007. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. *Br J Pharmacol* **152**: 795–804.
- Fattore L, Melis M, Fadda P, Pistis M, Fratta W. 2010. The endocannabinoid system and nondrug rewarding behaviours. *Exp Neurol* **224**: 23–36.
- Fattore L, Spano MS, Altea S, Fadda P, Fratta W. 2010. Drug- and cue-induced reinstatement of cannabinoid-seeking behaviour in male and female rats: influence of ovarian hormones. *Br J Pharmacol* **160**: 724–735.
- Gamaledin IH, Trigo JM, Gueye AB, Zvonok A, Makriyannis A, Goldberg SR, Le Foll B. 2015. Role of the endogenous cannabinoid system in nicotine addiction: novel insights. *Front Psychiatry* **6**: 1–12.
- Gould J. 2015. The cannabis crop. *Nature* **525**: S2–S3.
- Han X, He Y, Bi GH, Zhang HY, Song R, Liu QR, Egan JM, Gardner EL, Li J, Xi ZX. 2017. CB1 receptor activation on Vglut2-expressing glutamatergic neurons underlies Δ^9 -tetrahydrocannabinol (Δ^9 -THC)-induced aversive effects in mice. *Sci Rep* **7**: 12315.
- Haney M. 2008. Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. *Addict Biol* **14**: 9–21.
- Harte-Hargrove LC, Dow-Edwards DL. 2012. Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety. *Behav Brain Res* **231**: 48–59.
- Haug NA, Padula CB, Sottile JE, Vandrey R, Heinz AJ, Bonn-Miller MO. 2017. Cannabis use patterns and motives: a comparison of younger, middle-aged, and older medical cannabis dispensary patients. *Addict Behav* **72**: 14–20.
- Hayase T. 2017. Epigenetic mechanisms associated with addiction-related behavioural effects of nicotine and/or cocaine. *Behav Pharmacol* **28**: 493–511.
- Hempel BJ, Wakeford AG, Nelson KH, Clasen MM, Woloshchuk CJ, Riley AL. 2017. An assessment of sex differences in Δ^9 -tetrahydrocannabinol (THC) taste and place conditioning. *Pharmacol Biochem Behav* **153**: 69–75.
- Hyman SE, Malenka RC, Nestler EJ. 2006. Neural mechanisms of addiction: the role of reward-related learning and memory. *Annu Rev Neurosci* **29**: 565–598.
- Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, Sanislow C, Wang P. 2010. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. *Am J Psychiatry* **167**: 748–751.
- Johnson KA, Lovinger DM. 2016. Presynaptic G protein-coupled receptors: gatekeepers of addiction? *Front Cell Neurosci* **10**: 264.
- Justinova Z, Tanda G, Redhi GH, Goldberg SR. 2003. Self-administration of Δ^9 -tetrahydrocannabinol (THC) by drug naive squirrel monkeys. *Psychopharmacology* **169**: 135–140.
- Justinova Z, Tanda G, Munzar P, Goldberg SR. 2004. The opioid antagonist naltrexone reduces the reinforcing effects of Δ^9 -tetrahydrocannabinol (THC) in squirrel monkeys. *Psychopharmacology* **173**: 186–194.
- Justinova Z, Goldberg SR, Heishman SJ, Tanda G. 2005. Self-administration of cannabinoids by experimental animals and human marijuana smokers. *Pharmacol Biochem Behav* **81**: 285–299.
- Kleczkowska P, Smaga I, Filip M, Bujalska-Zadrozny M. 2015. Cannabinoid ligands and alcohol addiction: a promising therapeutic tool or a humbug? *Neurotox Res* **29**: 173–196.
- López-Moreno J, Lopez-Jimenez A, Gorriti M, De Fonseca F. 2010. Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors. *Curr Drug Targets* **11**: 406–428.
- López-Moreno JA, Echeverry-Alzate V, Bühler K. 2012. The genetic basis of the endocannabinoid system and drug addiction in humans. *J Psychopharmacology* **26**: 133–143.
- Mackintosh NJ. 1974. *The psychology of animal learning*. Academic Press, London.
- Maldonado R, Valverde O, Berrendero F. 2006. Involvement of the endocannabinoid system in drug addiction. *Trends Neurosci* **29**: 225–232.
- Manwell LA, Charchoglyan A, Brewer D, Matthews BA, Heipel H, Mallet PE. 2014. A vaporized Δ^9 -tetrahydrocannabinol (Δ^9 -THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents. *J Pharmacol Toxicol Met* **70**: 120–127.
- Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Ziegglänsberger W, et al. 2002. The endogenous cannabinoid system controls extinction of aversive memories. *Nature* **418**: 530.
- Marusich JA, Lefever TW, Antonazzo KR, Craft RM, Wiley JL. 2014. Evaluation of sex differences in cannabinoid dependence. *Drug Alcohol Depend* **137**: 20–28.
- Matias I, Di Marzo V. 2006. Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. *J Endocrinol Invest* **29**: 15–16.
- Mechoulam R, Hanus LO, Pertwee R, Howlett AC. 2014. Early phytocannabinoid chemistry to endocannabinoids and beyond. *Nat Rev Neurosci* **15**: 757–764.
- Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F. 2013. Endocannabinoid system and mood disorders: priming a target for new therapies. *Pharmacol Ther* **138**: 18–37.
- Milliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA. 2016. Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. *Front Neurosci* **10**: 153.
- Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schütz G, Wotjak CT, Lutz B, Marsicano G. 2007. Genetic dissection of behavioural and autonomic effects of Δ^9 -tetrahydrocannabinol in mice. *PLoS Biol* **5**: e269.
- Morales P, Reggio PH. 2017. An update on non-CB1, non-CB2 cannabinoid related G-protein-coupled receptors. *Cannabis Cannabinoid Res* **2**: 265–273.
- Moreira FA, Wotjak CT. 2010. Cannabinoids and anxiety. *Curr Top Behav Neurosci* **2**: 429–450.
- Murray JE, Bevins RA. 2010. Cannabinoid conditioned reward and aversion: behavioral and neural processes. *ACS Chem Neurosci* **1**: 265–278.
- Murray RM, Morrison PD, Henquet C, Forti MD. 2007. Cannabis, the mind and society: the hash realities. *Nat Rev Neurosci* **8**: 885–895.
- Pandolfo P, Vendruscolo LF, Sordi R, Takahashi RN. 2009. Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat—an animal model of attention deficit hyperactivity disorder. *Psychopharmacology* **205**: 319–326.
- Panlilio LV, Justinova Z, Goldberg SR. 2010. Animal models of cannabinoid reward. *Br J Pharmacol* **160**: 499–510.
- Panlilio LV, Justinova Z, Goldberg SR. 2013. Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. *Pharmacol Ther* **138**: 84–102.
- Parsons LH, Hurd YL. 2015. Endocannabinoid signalling in reward and addiction. *Nat Rev Neurosci* **16**: 579–594.
- Patel S, Hillard CJ. 2006. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. *J Pharmacol Exp Ther* **318**: 304–311.
- Patel S, Hill MN, Cheer JF, Wotjak CT, Holmes A. 2017. The endocannabinoid system as a target for novel anxiolytic drugs. *Neurosci Biobehav Rev* **76**: 56–66.
- Pava MJ, Woodward JJ. 2012. A review of the interactions between alcohol and the endocannabinoid system: implications for alcohol dependence and future directions for research. *Alcohol* **46**: 185–204.
- Pertwee RG. 2008. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ^9 -tetrahydrocannabinol, cannabidiol and Δ^9 -tetrahydrocannabivarin. *Br J Pharmacol* **153**: 199–215.
- Pintori N, Loi B, Mereu M. 2017. Synthetic cannabinoids: the hidden side of Spice drugs. *Behav Pharmacol* **28**: 409–419.
- Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N, Thompson MR, Dawson B, Mallet PE, Kashem MA, et al. 2008. Adolescent rats find repeated Δ^9 -THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. *Neuropsychopharmacology* **33**: 1113–1126.
- Rey AA, Purrio M, Viveros M, Lutz B. 2012. Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA receptors in the balance of GABAergic and glutamatergic neurotransmission. *Neuropsychopharmacology* **37**: 2624–2634.
- Riebe CJ, Pamplona FA, Kamprath K, Wotjak CT. 2012. Fear relief—toward a new conceptual frame work and what endocannabinoids gotta do with it. *Neuroscience* **204**: 159–185.
- Roma PG, Riley AL. 2005. Apparatus bias and the use of light and texture in place conditioning. *Pharmacol Biochem Behav* **82**: 163–169.
- Rubino T, Parolaro D. 2011. Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. *Front Behav Neurosci* **5**: 64.

- Sanchis-Segura C, Spanagel R. 2006. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. *Addict Biol* **11**: 2–38.
- Scherma M, Muntoni AL, Melis M, Fattore L, Fadda P, Fratta W, Pistis M. 2016. Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives. *Psychopharmacology* **233**: 1765–1777.
- Schramm-Sapota NL, Cha YM, Chaudhry S, Wilson WA, Swartzwelder HS, Kuhn CM. 2007. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. *Psychopharmacology* **191**: 867–877.
- Serrano A, Parsons LH. 2011. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. *Pharmacol Ther* **132**: 215–241.
- Sidhpura N, Parsons LH. 2011. Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. *Neuropharmacology* **61**: 1070–1087.
- Sloan ME, Gowin JL, Ramchandani VA, Hurd YL, Le Foll B. 2017. The endocannabinoid system as a target for addiction treatment: trials and tribulations. *Neuropharmacology* **124**: 73–83.
- Solinas M, Goldberg SR, Piomelli D. 2008. The endocannabinoid system in brain reward processes. *Br J Pharmacol* **154**: 369–383.
- Su H, Zhao M. 2017. Endocannabinoid mechanism in amphetamine-type stimulant use disorders: A short review. *J Clin Neurosci* **46**: 9–12.
- Szutorisz H, Hurd YL. 2018. High times for cannabis: epigenetic imprint and its legacy on brain and behavior. *Neurosci Biobehav Rev* **85**: 93–101.
- Tanda G, Goldberg SR. 2003. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms: a review of recent preclinical data. *Psychopharmacology* **169**: 115–134.
- Tanda G, Munzar P, Goldberg SR. 2000. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. *Nat Neurosci* **3**: 1073–1074.
- Tarragon E, Moreno JJ. 2018. Role of endocannabinoids on sweet taste perception, food preference, and obesity-related disorders. *Chem Senses* **43**: 3–16.
- Tzschentke TM. 2007. Review on CPP: measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. *Addict Biol* **12**: 227–462.
- Valjent E, Maldonado R. 2000. A behavioural model to reveal place preference to Δ^9 -tetrahydrocannabinol in mice. *Psychopharmacology* **147**: 436–438.
- Valjent E, Mitchell JM, Besson M, Caboche J, Maldonado R. 2002. Behavioural and biochemical evidence for interactions between Δ^9 -tetrahydrocannabinol and nicotine. *Br J Pharmacol* **135**: 564–578.
- Viñals X, Moreno E, Lanfumey L, Cordomi A, Pastor A, de La Torre R, Gasperini P, Navarro G, Howell LA, Pardo L, et al. 2015. Cognitive impairment induced by Δ^9 -tetrahydrocannabinol occurs through heteromers between cannabinoid CB1 and serotonin 5-HT2A receptors. *PLoS Biol* **13**: e1002194.
- Viveros MP, Marco EM, File SE. 2005. Endocannabinoid system and stress and anxiety responses. *Pharmacol Biochem Behav* **81**: 331–342.
- Wills KL, Parker LA. 2016. Effect of pharmacological modulation of the endocannabinoid system on opiate withdrawal: a review of the preclinical animal literature. *Front Pharmacol* **7**: 1–9.
- Wiskerke J, Pattij T, Schoffelmeer AN, De Vries TJ. 2008. The role of CB1 receptors in psychostimulant addiction. *Addict Biol* **13**: 225–238.
- Zou S, Kumar U. 2018. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. *Int J Mol Sci* **19**: E833.

Received April 16, 2018; accepted in revised form July 9, 2018.

Highway to hell or magic smoke? The dose-dependence of Δ^9 -THC in place conditioning paradigms

Rimas A. Kubilius, Paul M. Kaplick and Carsten T. Wotjak

Learn. Mem. 2018, **25**:

Access the most recent version at doi:[10.1101/lm.046870.117](https://doi.org/10.1101/lm.046870.117)

Supplemental Material

<http://learnmem.cshlp.org/content/suppl/2018/08/06/25.9.446.DC1>

References

This article cites 89 articles, 3 of which can be accessed free at:
<http://learnmem.cshlp.org/content/25/9/446.full.html#ref-list-1>

Creative Commons License

This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first 12 months after the full-issue publication date (see <http://learnmem.cshlp.org/site/misc/terms.xhtml>). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).